RxDoctor Payments Data

Joshua Atkinson, MD

Ophthalmology · Spring, TXNPI 1144607276

Payments from drug & device makers

$8,456in general payments, 2019–2025

Across 329 payments — averaging $25.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Tarsus Pharmaceuticals, Inc.$2K
  • Alcon$621
  • Sun Pharmaceutical Industries Inc.$562
  • Amgen$534
  • Ocular Therapeutix, Inc.$335
  • plus $2K from 20 others

What the payments were for

  • Consulting fees$87010%
  • Food & beverage$7,58690%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,456 in reported general payments places this provider in the 80th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$251,173
Medicare patients
678
Services billed
1,755

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine110$150,184
TyrvayaVarenicline Tartrate55$74,047
XiidraLifitegrast47$67,952
LumiganBimatoprost122$62,821
Cyclosporine41$24,275
XdemvyLotilaner13$23,232
VyzultaLatanoprostene Bunod38$17,836
CombiganBrimonidine Tartrate/Timolol46$16,452
MieboPerfluorohexyloctane/Pf22$15,763
CequaCyclosporine15$15,257
SimbrinzaBrinzolamide/Brimonidine Tart34$9,908
RhopressaNetarsudil Mesylate20$9,630
Latanoprost866$9,312
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol44$8,927
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat431$7,568

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$2,174$234,214292 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo$268$101,552107 claims
Oyster Point Pharma, Inc.Tyrvaya$256$74,04755 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$2,016$23,23213 claims
Sun Pharmaceutical Industries Inc.Cequa$562$15,25715 claims
AlconSimbrinza$621$9,90834 claims
Aerie Pharmaceuticals, Inc.Rhopressa$23$9,63020 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCZylet$164$5,40616 claims
Eyevance Pharmaceuticals LLCTobradex St$55$2,79012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in Spring

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →